The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple ...

GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to treat type 2 diabetes and, in some cases, obesity. "The glucagon-like peptide (GLP-1 ...

Glucagon-like peptide-1 (GLP-1) receptors, expressed in the central nervous system and peripheral tissues, have been found to affect gut motility. GLP-1 and its analog ROSE-010 have been shown to ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

As the indications and demand for glucagon-like peptide-1 (GLP-1) agonist drugs continue to expand, the real-world GLP-1 research and data-driven insights from Prime Therapeutics LLC (Prime) help ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

Key Takeaways More people with type 1 diabetes are severely obese and using GLP-1 drugs for weight lossExperts are concerned ...

Skinny jab? Try skinny juice. For centuries, it’s been enjoyed by people in South America — and it’s long been linked to ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.